Validation and Application of The Stellar Abundances and atmospheric Parameter Pipeline to derive fundamental parameters of stars in the era of large-scale stellar surveys

SAPP is a pipeline designed to determine accurate parameters of stars in large surveys like Gaia-ESO and Gaia. It combines various observations, including spectra, photometry, astrometry, and asteroseismic data, using Bayesian inference. Validated with benchmark stars, SAPP breaks degeneracies between parameters, yielding precise results. For effective temperature, the typical error is about 100 K, with spectroscopic models dominating uncertainty. Log(g) uncertainty depends on observables, ranging from 0.03 dex to 0.06 dex. Metallicities are recovered with a precision of 0.03 dex for PLATO targets, improved by seismic priors. SAPP also employs an iterative scheme using nu_max = f(Teff, log g) relation, yielding robust results with small differences in temperature and metallicity. It provides fundamental parameters accurate within 1%, meeting PLATO’s goals and enabling exploration of the Galactic structure, including Radial Migration and Age Metallicity Relation. SAPP is used to investigate the alpha-poor and alpha-rich populations in the Galactic disc using Gaia-ESO spectra, Gaia EDR3 astrometry, and photometry. Non-Local Thermodynamic Equilibrium models determine parameters and abundances. A cold metal-poor alpha-poor disc is found in local distributions, suggesting co-evolution of the thick and thin disc. These distributions show well-defined trends in age and kinematic space (Vφ ). SAPP’s accurate age and abundance estimations contribute to understanding Galactic characteristics such as Radial Gradient Measurements

The Prince and the Pauper: Evidence for the early high-redshift formation of the Galactic α\alpha-poor disc population

Context. The presence of [$\alpha$/Fe]-[Fe/H] bi-modality in the Milky Way disc has animated the Galactic archaeology community since more than two decades. Aims. Our goal is to investigate the chemical, temporal, and kinematical structure of the Galactic discs using abundances, kinematics, and ages derived self-consistently with the new Bayesian framework SAPP. Methods. We employ the public Gaia-ESO spectra, as well as Gaia EDR3 astrometry and photometry. Stellar parameters and chemical abundances are determined for 13 426 stars using NLTE models of synthetic spectra. Ages are derived for a sub-sample of 2 898 stars, including subgiants and main-sequence stars. The sample probes a large range of Galactocentric radii, $\sim$ 3 to 12 kpc, and extends out of the disc plane to $\pm$ 2 kpc. Results. Our new data confirm the known bi-modality in the [Fe/H] - [$\alpha$/Fe] space, which is often viewed as the manifestation of the chemical thin and thick discs. The over-densities significantly overlap in metallicity, age, and kinematics, and none of these is a sufficient criterion for distinguishing between the two disc populations. Different from previous studies, we find that the $\alpha$-poor disc population has a very extended [Fe/H] distribution and contains $\sim$ 20$\%$ old stars with ages of up to $\sim$ 11 Gyr. Conclusions. Our results suggest that the Galactic thin disc was in place early, at look-back times corresponding to redshifts z $\sim$ 2 or more. At ages $\sim$ 9 to 11 Gyr, the two disc structures shared a period of co-evolution. Our data can be understood within the clumpy disc formation scenario that does not require a pre-existing thick disc to initiate a formation of the thin disc. We anticipate that a similar evolution can be realised in cosmological simulations of galaxy formation.Comment: 14 pages, 10 figures, re-submitted to A&

The SAPP pipeline for the determination of stellar abundances and atmospheric parameters of stars in the core program of the PLATO mission

We introduce the SAPP (Stellar Abundances and atmospheric Parameters Pipeline), the prototype of the code that will be used to determine parameters of stars observed within the core program of the PLATO space mission. The pipeline is based on the Bayesian inference and provides effective temperature, surface gravity, metallicity, chemical abundances, and luminosity. The code in its more general version has a much wider range of potential applications. It can also provide masses, ages, and radii of stars and can be used with stellar types not targeted by the PLATO core program, such as red giants. We validate the code on a set of 27 benchmark stars that includes 19 FGK-type dwarfs, 6 GK-type subgiants, and 2 red giants. Our results suggest that combining various observables is the optimal approach, as this allows the degeneracies between different parameters to be broken and yields more accurate values of stellar parameters and more realistic uncertainties. For the PLATO core sample, we obtain a typical uncertainty of 27 (syst.) ± 37 (stat.) K for Teff, 0.00 ± 0.01 dex for log g, 0.02 ± 0.02 dex for metallicity [Fe/H], −0.01 ± 0.03 R⊙ for radii, −0.01 ± 0.05 M⊙ for stellar masses, and −0.14 ± 0.63 Gyr for ages. We also show that the best results are obtained by combining the νmax scaling relation with stellar spectra. This resolves the notorious problem of degeneracies, which is particularly important for F-type stars

New genetic loci link adipose and insulin biology to body fat distribution.

Body fat distribution is a heritable trait and a well-established predictor of adverse metabolic outcomes, independent of overall adiposity. To increase our understanding of the genetic basis of body fat distribution and its molecular links to cardiometabolic traits, here we conduct genome-wide association meta-analyses of traits related to waist and hip circumferences in up to 224,459 individuals. We identify 49 loci (33 new) associated with waist-to-hip ratio adjusted for body mass index (BMI), and an additional 19 loci newly associated with related waist and hip circumference measures (P < 5 × 10(-8)). In total, 20 of the 49 waist-to-hip ratio adjusted for BMI loci show significant sexual dimorphism, 19 of which display a stronger effect in women. The identified loci were enriched for genes expressed in adipose tissue and for putative regulatory elements in adipocytes. Pathway analyses implicated adipogenesis, angiogenesis, transcriptional regulation and insulin resistance as processes affecting fat distribution, providing insight into potential pathophysiological mechanisms

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Health-status outcomes with invasive or conservative care in coronary disease

BACKGROUND In the ISCHEMIA trial, an invasive strategy with angiographic assessment and revascularization did not reduce clinical events among patients with stable ischemic heart disease and moderate or severe ischemia. A secondary objective of the trial was to assess angina-related health status among these patients. METHODS We assessed angina-related symptoms, function, and quality of life with the Seattle Angina Questionnaire (SAQ) at randomization, at months 1.5, 3, and 6, and every 6 months thereafter in participants who had been randomly assigned to an invasive treatment strategy (2295 participants) or a conservative strategy (2322). Mixed-effects cumulative probability models within a Bayesian framework were used to estimate differences between the treatment groups. The primary outcome of this health-status analysis was the SAQ summary score (scores range from 0 to 100, with higher scores indicating better health status). All analyses were performed in the overall population and according to baseline angina frequency. RESULTS At baseline, 35% of patients reported having no angina in the previous month. SAQ summary scores increased in both treatment groups, with increases at 3, 12, and 36 months that were 4.1 points (95% credible interval, 3.2 to 5.0), 4.2 points (95% credible interval, 3.3 to 5.1), and 2.9 points (95% credible interval, 2.2 to 3.7) higher with the invasive strategy than with the conservative strategy. Differences were larger among participants who had more frequent angina at baseline (8.5 vs. 0.1 points at 3 months and 5.3 vs. 1.2 points at 36 months among participants with daily or weekly angina as compared with no angina). CONCLUSIONS In the overall trial population with moderate or severe ischemia, which included 35% of participants without angina at baseline, patients randomly assigned to the invasive strategy had greater improvement in angina-related health status than those assigned to the conservative strategy. The modest mean differences favoring the invasive strategy in the overall group reflected minimal differences among asymptomatic patients and larger differences among patients who had had angina at baseline

Initial invasive or conservative strategy for stable coronary disease

BACKGROUND Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain. METHODS We randomly assigned 5179 patients with moderate or severe ischemia to an initial invasive strategy (angiography and revascularization when feasible) and medical therapy or to an initial conservative strategy of medical therapy alone and angiography if medical therapy failed. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. A key secondary outcome was death from cardiovascular causes or myocardial infarction. RESULTS Over a median of 3.2 years, 318 primary outcome events occurred in the invasive-strategy group and 352 occurred in the conservative-strategy group. At 6 months, the cumulative event rate was 5.3% in the invasive-strategy group and 3.4% in the conservative-strategy group (difference, 1.9 percentage points; 95% confidence interval [CI], 0.8 to 3.0); at 5 years, the cumulative event rate was 16.4% and 18.2%, respectively (difference, 121.8 percentage points; 95% CI, 124.7 to 1.0). Results were similar with respect to the key secondary outcome. The incidence of the primary outcome was sensitive to the definition of myocardial infarction; a secondary analysis yielded more procedural myocardial infarctions of uncertain clinical importance. There were 145 deaths in the invasive-strategy group and 144 deaths in the conservative-strategy group (hazard ratio, 1.05; 95% CI, 0.83 to 1.32). CONCLUSIONS Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a median of 3.2 years. The trial findings were sensitive to the definition of myocardial infarction that was used